Antisense therapy has generated waves of enthusiasm and disappointment. With a new drug about to be submitted for approval, is it on the cusp of becoming established as a platform technology?
Access options
Subscribe to Journal
Get full journal access for 1 year
$259.00
only $21.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
from$8.99
All prices are NET prices.
Rights and permissions
About this article
Cite this article
Jones, D. The long march of antisense. Nat Rev Drug Discov 10, 401–402 (2011). https://doi.org/10.1038/nrd3474
Published:
Issue Date:
Further reading
-
Strict conformational demands of RNA cleavage in bulge-loops created by peptidyl-oligonucleotide conjugates
Nucleic Acids Research (2020)
-
Targeting Mutant KRAS for Anticancer Therapy
Current Topics in Medicinal Chemistry (2019)
-
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
Journal of Experimental & Clinical Cancer Research (2018)
-
‘Dual’ peptidyl-oligonucleotide conjugates: Role of conformational flexibility in catalytic cleavage of RNA
Biomaterials (2017)
-
Identifying novel antiviral targets against enterovirus 71: where are we?
Future Virology (2017)